PortalPublikationenComparative efficacy and safety of the duodenal-jejunal bypa...

Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study

Standard

Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study. / Laubner, Katharina; Riedel, Nina; Fink, Katharina; Holl, Reinhard W; Welp, Reinhard; Kempe, Hans-Peter; Lautenbach, Anne; Schlensak, Matthias; Stengel, Rainer; Eberl, Thomas; Dederichs, Frank; Schwacha, Henning; Seufert, Jochen; Aberle, Jens.

in: DIABETES OBES METAB, Jahrgang 20, Nr. 8, 08.2018, S. 1868-1877.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Laubner, K, Riedel, N, Fink, K, Holl, RW, Welp, R, Kempe, H-P, Lautenbach, A, Schlensak, M, Stengel, R, Eberl, T, Dederichs, F, Schwacha, H, Seufert, J & Aberle, J 2018, 'Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study', DIABETES OBES METAB, Jg. 20, Nr. 8, S. 1868-1877. https://doi.org/10.1111/dom.13300

APA

Laubner, K., Riedel, N., Fink, K., Holl, R. W., Welp, R., Kempe, H-P., Lautenbach, A., Schlensak, M., Stengel, R., Eberl, T., Dederichs, F., Schwacha, H., Seufert, J., & Aberle, J. (2018). Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study. DIABETES OBES METAB, 20(8), 1868-1877. https://doi.org/10.1111/dom.13300

Vancouver

Laubner K, Riedel N, Fink K, Holl RW, Welp R, Kempe H-P et al. Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study. DIABETES OBES METAB. 2018 Aug;20(8):1868-1877. https://doi.org/10.1111/dom.13300

Bibtex

@article{89adbfb96c194dd58cdc0bfc2dc24558,
title = "Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study",
abstract = "AIMS: The duodenal-jejunal bypass liner (DJBL) is an endoscopic device mimicking surgical duodenal-jejunal bypass, and is indicated for the treatment of obesity-associated type 2 diabetes mellitus. This analysis was conducted to evaluate the efficacy and safety of the DJBL in comparison to lifestyle changes and antidiabetic drugs.MATERIALS AND METHODS: To determine the efficacy and long-term safety of the DJBL, data concerning 235 obese patients with type 2 diabetes mellitus from the German DJBL registry were analysed. For comparison with standard treatment, propensity-score-matching with patients from the German DPV registry, including the matching parameters sex, age, diabetes duration, baseline BMI and baseline HbA1c, was applied. The final matched cohort consisted of 111 patients in the DJBL group and 222 matched control DPV patients.RESULTS: Mean treatment time with the DJBL was 47.5 ± 12.2 weeks, mean BMI reduction was 5.0 kg/m2 (P < .001) and mean HbA1c reduction was 1.3% (11.9 mmol/mol) (P < .001). Reduction of antidiabetic medications and improvements in other metabolic and cardiovascular risk parameters was observed. In comparison to the matched control group, mean reductions in HbA1c (-1.37% vs -0.51% [12.6 vs 3.2 mmol/mol]; P < .0001) and BMI (-3.02 kg/m2 vs -0.39 kg/m2 ; P < .0001) were significantly higher. Total cholesterol, LDL cholesterol and blood pressure were also significantly better.CONCLUSION: This study provides the largest, so far, hypothesis-generating evidence for a putative positive risk/benefit ratio for treatment of obese patients with type 2 diabetes mellitus with the DJBL as an alternative treatment option for this patient population.",
keywords = "Anastomosis, Surgical, Bariatric Surgery, Body Mass Index, Case-Control Studies, Cohort Studies, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Duodenum, Endoscopy, Gastrointestinal, Female, Follow-Up Studies, Germany, Humans, Hyperglycemia, Hypoglycemic Agents, Jejunum, Male, Middle Aged, Obesity, Morbid, Postoperative Complications, Prospective Studies, Registries, Risk Assessment, Weight Loss, Comparative Study, Journal Article, Observational Study, Research Support, Non-U.S. Gov't",
author = "Katharina Laubner and Nina Riedel and Katharina Fink and Holl, {Reinhard W} and Reinhard Welp and Hans-Peter Kempe and Anne Lautenbach and Matthias Schlensak and Rainer Stengel and Thomas Eberl and Frank Dederichs and Henning Schwacha and Jochen Seufert and Jens Aberle",
note = "{\textcopyright} 2018 John Wiley & Sons Ltd.",
year = "2018",
month = aug,
doi = "10.1111/dom.13300",
language = "English",
volume = "20",
pages = "1868--1877",
journal = "DIABETES OBES METAB",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "8",

}

RIS

TY - JOUR

T1 - Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study

AU - Laubner, Katharina

AU - Riedel, Nina

AU - Fink, Katharina

AU - Holl, Reinhard W

AU - Welp, Reinhard

AU - Kempe, Hans-Peter

AU - Lautenbach, Anne

AU - Schlensak, Matthias

AU - Stengel, Rainer

AU - Eberl, Thomas

AU - Dederichs, Frank

AU - Schwacha, Henning

AU - Seufert, Jochen

AU - Aberle, Jens

N1 - © 2018 John Wiley & Sons Ltd.

PY - 2018/8

Y1 - 2018/8

N2 - AIMS: The duodenal-jejunal bypass liner (DJBL) is an endoscopic device mimicking surgical duodenal-jejunal bypass, and is indicated for the treatment of obesity-associated type 2 diabetes mellitus. This analysis was conducted to evaluate the efficacy and safety of the DJBL in comparison to lifestyle changes and antidiabetic drugs.MATERIALS AND METHODS: To determine the efficacy and long-term safety of the DJBL, data concerning 235 obese patients with type 2 diabetes mellitus from the German DJBL registry were analysed. For comparison with standard treatment, propensity-score-matching with patients from the German DPV registry, including the matching parameters sex, age, diabetes duration, baseline BMI and baseline HbA1c, was applied. The final matched cohort consisted of 111 patients in the DJBL group and 222 matched control DPV patients.RESULTS: Mean treatment time with the DJBL was 47.5 ± 12.2 weeks, mean BMI reduction was 5.0 kg/m2 (P < .001) and mean HbA1c reduction was 1.3% (11.9 mmol/mol) (P < .001). Reduction of antidiabetic medications and improvements in other metabolic and cardiovascular risk parameters was observed. In comparison to the matched control group, mean reductions in HbA1c (-1.37% vs -0.51% [12.6 vs 3.2 mmol/mol]; P < .0001) and BMI (-3.02 kg/m2 vs -0.39 kg/m2 ; P < .0001) were significantly higher. Total cholesterol, LDL cholesterol and blood pressure were also significantly better.CONCLUSION: This study provides the largest, so far, hypothesis-generating evidence for a putative positive risk/benefit ratio for treatment of obese patients with type 2 diabetes mellitus with the DJBL as an alternative treatment option for this patient population.

AB - AIMS: The duodenal-jejunal bypass liner (DJBL) is an endoscopic device mimicking surgical duodenal-jejunal bypass, and is indicated for the treatment of obesity-associated type 2 diabetes mellitus. This analysis was conducted to evaluate the efficacy and safety of the DJBL in comparison to lifestyle changes and antidiabetic drugs.MATERIALS AND METHODS: To determine the efficacy and long-term safety of the DJBL, data concerning 235 obese patients with type 2 diabetes mellitus from the German DJBL registry were analysed. For comparison with standard treatment, propensity-score-matching with patients from the German DPV registry, including the matching parameters sex, age, diabetes duration, baseline BMI and baseline HbA1c, was applied. The final matched cohort consisted of 111 patients in the DJBL group and 222 matched control DPV patients.RESULTS: Mean treatment time with the DJBL was 47.5 ± 12.2 weeks, mean BMI reduction was 5.0 kg/m2 (P < .001) and mean HbA1c reduction was 1.3% (11.9 mmol/mol) (P < .001). Reduction of antidiabetic medications and improvements in other metabolic and cardiovascular risk parameters was observed. In comparison to the matched control group, mean reductions in HbA1c (-1.37% vs -0.51% [12.6 vs 3.2 mmol/mol]; P < .0001) and BMI (-3.02 kg/m2 vs -0.39 kg/m2 ; P < .0001) were significantly higher. Total cholesterol, LDL cholesterol and blood pressure were also significantly better.CONCLUSION: This study provides the largest, so far, hypothesis-generating evidence for a putative positive risk/benefit ratio for treatment of obese patients with type 2 diabetes mellitus with the DJBL as an alternative treatment option for this patient population.

KW - Anastomosis, Surgical

KW - Bariatric Surgery

KW - Body Mass Index

KW - Case-Control Studies

KW - Cohort Studies

KW - Diabetes Mellitus, Type 2

KW - Drug Therapy, Combination

KW - Duodenum

KW - Endoscopy, Gastrointestinal

KW - Female

KW - Follow-Up Studies

KW - Germany

KW - Humans

KW - Hyperglycemia

KW - Hypoglycemic Agents

KW - Jejunum

KW - Male

KW - Middle Aged

KW - Obesity, Morbid

KW - Postoperative Complications

KW - Prospective Studies

KW - Registries

KW - Risk Assessment

KW - Weight Loss

KW - Comparative Study

KW - Journal Article

KW - Observational Study

KW - Research Support, Non-U.S. Gov't

U2 - 10.1111/dom.13300

DO - 10.1111/dom.13300

M3 - SCORING: Journal article

C2 - 29569313

VL - 20

SP - 1868

EP - 1877

JO - DIABETES OBES METAB

JF - DIABETES OBES METAB

SN - 1462-8902

IS - 8

ER -